Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Deals Medical Device PIC

TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices

Fineline Cube Aug 28, 2026
Company Drug PIC

Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen

Fineline Cube Aug 28, 2026
Company Drug PIC

Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis

Fineline Cube Aug 28, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Aug 28, 2026
Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Fineline Cube Aug 28, 2026
Policy / Regulatory

NMPA Releases 68th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube May 15, 2023

The National Medical Products Administration (NMPA) has released the 68th batch of reference drugs for...

Company Medical Device

Basecare Medical to Acquire BMX Holdco for $40 Million, Expanding IVF Portfolio

Fineline Cube May 15, 2023

China-based in vitro fertilization (IVF) specialist, Suzhou Basecare Medical Co., Ltd (HKG: 2170), has announced...

Company Deals

Nona Biosciences Partners with PharmaEssentia for Harnessing Harbor Mice Technology

Fineline Cube May 12, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...

Company Deals

First Condor Biotechnology Secures Tens of Millions in Pre-Series A Financing for CAR-T Cell Trials

Fineline Cube May 12, 2023

First Condor Biotechnology, a Guangdong-based cell therapy developer, has reportedly secured tens of millions of...

Policy / Regulatory

China’s NHC and 13 Bureaus Launch Campaign to Rectify Pharmaceutical and Medical Services Practices

Fineline Cube May 12, 2023

The National Health Commission (NHC) along with 13 other bureaus has jointly released a notification...

Company

Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact

Fineline Cube May 12, 2023

Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023,...

Company Drug

Wuhan Institute’s Hexavalent Rotavirus Vaccine on Track for Priority Review by CDE

Fineline Cube May 12, 2023

The Center for Drug Evaluation (CDE) website has indicated that Wuhan Institute of Biological Products...

Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promise in Phase II Study for Male Androgenetic Alopecia

Fineline Cube May 12, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the conclusion of a randomized, double-blind, placebo-controlled...

Company Deals Digital

ZhenGe Biotech Partners with NNIT for Advanced Digitalization in Drug Development

Fineline Cube May 12, 2023

ZhenGe Biotech, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic...

Drug Legal / IP

CNIPA Releases Patent Linkage Decisions, Paving Way for Generic Drugs in China

Fineline Cube May 11, 2023

The China National Intellectual Property Administration (CNIPA) has released the latest batch of completed patent...

Company Drug

Guangdong Taienkang’s CKBA Ointment for Vitiligo Accepted for Review by China’s NMPA

Fineline Cube May 11, 2023

Guangdong Taienkang Pharmaceutical Co., Ltd, (SHE: 301263), a China-based pharmaceutical company, has announced that the...

Company Drug

Mabwell’s B7-H3 Targeting ADC 7MW3711 Accepted for Review by China’s NMPA

Fineline Cube May 11, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that its...

Company Drug

CStone Pharmaceuticals’ Partner Servier Secures EU Approvals for IDH1 Inhibitor Tibsovo

Fineline Cube May 11, 2023

CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has announced receiving two new indication approvals for...

Company Drug

Innovent Biologics’ Mazdutide Showcases Weight Loss Efficacy in Phase II Study for Chinese Adults

Fineline Cube May 11, 2023

China-based Innovent Biologics Inc., (HKG: 1801), has announced that a Phase II clinical study assessing...

Policy / Regulatory

Beijing Medical Insurance Bureau Announces Key Healthcare Initiatives and BMI Expansion

Fineline Cube May 11, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification outlining key tasks for the...

Company Drug

Joincare Pharmaceutical Receives NMPA Approval for Triptorelin Microspheres for Prostate Cancer

Fineline Cube May 11, 2023

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced that...

Company Drug

Zai Lab’s Repotrectinib on Track for Priority Review by China’s CDE for ROS1+ NSCLC

Fineline Cube May 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Zai Lab Ltd’s (NASDAQ: ZLAB)...

Company Drug

Sichuan Kelun Pharmaceutical’s A166 Anti-HER2 ADC NDA Accepted for Review by NMPA

Fineline Cube May 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has announced that the...

Company Deals

Suzhou Porton Biologics and Synbio Technologies Partner to Advance Cell and Gene Therapy in China

Fineline Cube May 10, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company Drug

Mabwell Bioscience’s 9MW3911 Receives NMPA Approval for Clinical Trial in Advanced Tumors

Fineline Cube May 10, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical...

Posts pagination

1 … 574 575 576 … 713

Recent updates

  • Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma
  • Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
  • HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
  • AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
  • Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Company Drug

HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.